Name: Linnea Burman
New title: President of the neurovascular business, Medtronic
Previous title: General manager of enabling technologies, cranial and spinal technologies business, Medtronic
Medtronic has promoted Linnea Burman to president of the neurovascular business, which is focused on stroke treatment, the device maker said in a Tuesday announcement.
She will oversee the portfolio strategy, product development, commercial execution and financial performance of the unit, reporting to Brett Wall, president of the neuroscience portfolio.
Burman previously was general manager of enabling technologies in Medtronic’s cranial and spinal technologies division, a business she helped establish. In the role, she led commercial growth strategies and drove a culture of collaboration, the company said.
The neuroscience portfolio, Medtronic’s second-largest operating segment after cardiovascular, encompasses three divisions: cranial and spinal technologies, specialty therapies and neuromodulation. The neurovascular unit that Burman will lead falls within the specialty therapies division.
“I look forward to working with my new team to build on our proven track record of advancing stroke care practices, fostering new partnerships within the neurovascular community, and developing effective therapies grounded in compelling clinical evidence,” Burman said in a statement.
Burman replaces Dan Volz, who is moving into the newly created role of senior vice president of global commercial transformation. Volz will lead a company-wide effort to modernize commercial strategies and go-to-market approaches.